Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Humanigen Is Getting Hammered Today

By Cory Renauer – Sep 9, 2021 at 12:04PM

Key Points

  • Despite the drug's achieving the primary endpoint in a pivotal phase 3 trial, the FDA denied Humanigen's request for emergency use authorization of lenzilumab.
  • The agency cited safety concerns that outweigh positive efficacy as the reason for denying the request.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An attempt to earn authorization for lenzilumab hit a wall at the FDA.

What happened

Humanigen (HGEN -2.41%) stock is sinking after the clinical-stage biopharmaceutical company shared devastating news. The FDA has declined Humanigen's request for emergency use authorization of lenzilumab, sending the biotech stock 52.1% lower as of 11:38 a.m. EDT on Thursday.

So what 

As a pre-commercial company without any revenue yet, Humanigen had a lot riding on the potential authorization of lenzilumab to treat hospitalized COVID-19 patients. Following positive clinical trial results the company presented in May, a green light seemed more than reasonable.

Frustrated stock trader.

Image source: Getty Images.

The FDA told Humanigen the clinical benefits presented aren't enough to outweigh the risks, at least based on available data. The FDA invited Humanigen to submit further data supporting authorization of lenzilumab if it becomes available.

The FDA's invitation wasn't any consolation because leaving the door open for new data is standard procedure when the agency isn't willing to greenlight a new drug with information available at the moment.

Now what

Humanigen isn't even close to giving up on lenzilumab. The company is going to continue preparing for a U.S. launch while waiting for results from the ongoing ACTIV-5/BET-B trial. This phase 3 study sponsored by the National Institute of Allergy and Infectious Diseases is expected to wrap up at the end of 2021. 

During the phase 3 trial, dubbed LIVE-AIR, patients randomized to receive lenzilumab were 90% more likely to survive without help from a ventilator. It's hard to see how Humanigen is going to convince the FDA to change its stance on lenzilumab if the reported success of LIVE-AIR wasn't strong enough to overcome the risks that prevented its authorization.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Humanigen Inc Stock Quote
Humanigen Inc
$0.14 (-2.41%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.